The expression of vasohibin‑1 and its prognostic significance in bladder cancer
- Authors:
- Published online on: August 18, 2017 https://doi.org/10.3892/etm.2017.4969
- Pages: 3477-3484
-
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Angiogenesis is important in the development of solid tumors. Vasohibin‑1 (VASH‑1) is an endothelium‑derived protein that acts as an inhibitor of angiogenesis in many different types of cancer. However, the expression of VASH‑1 and its clinical value in bladder cancer remain unknown. The current study analyzed the expression of VASH‑1, as well as the expression of the angiogenesis‑related factors vascular endothelial growth factor‑A, hypoxia inducible factor‑1α and cluster of differentiation 34 in bladder cancer tissues from 50 patients using immunohistochemistry. The associations between the expression of these factors and the clinicopathological characteristics of the patients were assessed. The current study demonstrated that VASH‑1 is primarily expressed in the cytoplasm of bladder cancer cells and in a fraction of vascular endothelial cells. Furthermore, the expression of VASH‑1 was positively associated with the tumor stage (P<0.01), pathological grade (P<0.01) and distant metastasis (P<0.05) but not with patient age or sex (P>0.05). Spearman rank correlation tests indicated that levels of those four factors were positively correlated with each other. Kaplan‑Meier analysis indicated that high expression of these four factors was significantly associated with lower 5‑year overall survival and progression‑free survival rates. Collectively, the results of the current study suggest that VASH‑1 is clinically significant in bladder cancer and its high expression may predict the progression and prognosis of patients with bladder cancer. The present study also implies that VASH‑1 may be a novel target for vascular targeting therapy.
